PT-141 for Weight Loss: What the Evidence Shows
PT-141 (bremelanotide) is a melanocortin-receptor agonist — the same system that regulates body weight — which has fueled viral claims it is a fat-loss peptide. Here is what the published science does, and does not, support.
How It Works
The melanocortin-4 receptor (MC4R) in the hypothalamus regulates appetite and energy balance. Loss-of-function MC4R mutations are the most common single-gene cause of human obesity, and gain-of-function variants protect against it (PMID 12646665, 26814590, 31002796). The mechanism the viral claim leans on is genuine.
PT-141 is bremelanotide, a melanocortin-receptor agonist FDA-approved only for hypoactive sexual desire disorder in premenopausal women, dosed as-needed by injection — not as a daily metabolic therapy (PMID 31893927, 33455598, 31599840).
The MC4R agonist actually proven to cause weight loss is setmelanotide — 80% of POMC-deficiency and 45% of LEPR-deficiency patients hit ≥10% loss — but chiefly in rare genetic obesity, not the general population (PMID 33137293). PT-141 is a different molecule with no such weight-loss evidence.
Bremelanotide transiently raises blood pressure, causes nausea in ~40% of users, and — with repeated daily dosing — produced focal hyperpigmentation in over a third of subjects. Its as-needed label exists to avoid exactly the chronic exposure that weight-loss use would require (PMID 35147466).
What the Data Shows
Key Takeaways
- PT-141 is bremelanotide, a melanocortin-receptor agonist FDA-approved only for hypoactive sexual desire disorder in premenopausal women, given as-needed (PMID 31893927, 31599840).
- The MC4R pathway genuinely regulates body weight: MC4R loss-of-function is the most common single-gene cause of obesity, and gain-of-function variants protect against it (PMID 12646665, 26814590, 31002796).
- The one MC4R agonist proven to cause meaningful weight loss is setmelanotide — 80% of POMC-deficiency and 45% of LEPR-deficiency patients reached ≥10% loss — but in rare genetic obesity, not the general population (PMID 33137293).
- Bremelanotide commonly causes nausea (~40% vs 1.3% placebo) and flushing, transiently raises blood pressure, and should be used cautiously in anyone at cardiovascular risk (PMID 35147466).
- Repeated daily bremelanotide dosing caused focal hyperpigmentation in over a third of subjects — a reason its label is as-needed rather than a daily regimen (PMID 35147466).
- There are no published, peer-reviewed human trials of PT-141 for weight loss. The widely-shared "Phase 2 tirzepatide combo" figures come from an unpublished, company-described study that cannot be independently verified.
- Whether PT-141’s melanocortin activity is potent or selective enough to reduce body weight in people without genetic MC4R-pathway defects is untested.
- The long-term safety of chronic daily PT-141 dosing over months — as weight-loss use would require — has not been established.
- How PT-141 would interact with GLP-1/GIP drugs like tirzepatide on weight, blood pressure, and nausea is unknown from published data.
- Any weight effect of melanocortin agonism must be weighed against its blood-pressure effect, a long-standing obstacle for melanocortin-based obesity drugs (PMID 21062377).
Frequently Asked Questions
Does PT-141 cause weight loss?
There are no published human trials showing PT-141 (bremelanotide) causes weight loss. It acts on the melanocortin system, which does regulate body weight, but the MC4R agonist actually proven to reduce weight is setmelanotide — and mainly in people with rare genetic obesity, not the general population (PMID 33137293). A viral claim of 4.4% weight loss with tirzepatide comes from an unpublished company study that cannot be independently verified.
Is PT-141 the same as the MC4R weight-loss drug setmelanotide?
No. Both are melanocortin agonists, but PT-141 (bremelanotide) is FDA-approved only for hypoactive sexual desire disorder and dosed as-needed, while setmelanotide is a separate drug approved for specific genetic obesity syndromes (PMID 31893927, 33137293).
Why do people say PT-141 helps with fat loss?
Because it activates the melanocortin system, and MC4R — the receptor whose loss causes human obesity and whose activation via setmelanotide drives weight loss — is central to appetite control. That real biology gets stretched into claims about PT-141 specifically, which has no published weight-loss evidence (PMID 12646665).
What are the risks of using PT-141 for weight loss?
Common side effects include nausea (~40%), flushing, and headache; it transiently raises blood pressure and, with repeated daily dosing, caused focal hyperpigmentation in over a third of users. Chronic daily use for weight loss carries risks its as-needed label was designed to avoid (PMID 35147466).
Is PT-141 approved for weight loss?
No. PT-141/bremelanotide is FDA-approved only for hypoactive sexual desire disorder in premenopausal women. It is not approved for weight loss (PMID 31893927).
🔬 Research-Grade Source
Swiss Chems publishes third-party HPLC COAs for selected products — vendor-published, a claim to verify. HighPeptides' primary vendor reference for peptides.
Browse Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
PT-141/bremelanotide is FDA-approved only for hypoactive sexual desire disorder; it is not approved for weight loss. Consult a licensed clinician before using any peptide.